CytoGenix seeks patent for cancer treatment

By Elaine Rigoli

Tampa, Fla., Aug. 24 - CytoGenix, Inc. said it has filed a patent application entitled "Single Stranded Expression Systems for Cancer Genetics and Other Applications" with the U.S. Patent and Trademark Office.

The patent application is based on the results of recent experiments, which show that the company's proprietary ssDNA technology effectively combats some types of tumor growth and can be used to silence cancer genes, according to a news release.

"This patent application seeks protection for use of this technology in cancer treatment, in parallel with our patent applications filed for use of the ssDNA technology in antiviral, anti-inflammatory and antibacterial applications," chief executive officer Malcolm Skolnick said in the release.

CytoGenix is a Houston-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.